Cardinal Health, Inc. (CAH): analysis and signal as of September 4, 2026

Published on September 5, 2026 at 07:15 · Updated on September 5, 2026 at 07:15 · by Aurélien Ambert, QDNA

Exchange : NYSE · Sector : Distribution Services

In short

The signal is weak, with a vote of 2/3 in favor of the positive scenario. The absence of verified fundamental ratios makes it impossible to determine whether the stock represents a quality value or a value trap.

Current signal: weak (vote 2/3)
Deterministic score: +1.5 → signal expected by the scale : moderate (September 10, 2026)
Layers: fundamentals : –, price : positive, risks : positive

Triggered rules

Rule	Weight
favors a high and durable return on invested capital (ROIC), a marker of a lasting moat	+2.0
penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower)	-1.5
favors robust fundamental health (high Piotroski F-Score)	+1.5
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

The Cardinal Health case has a defensive sector profile, a bullish macroeconomic regime and a supportive technical picture, but no verified fundamental figure allows one to decide between a quality value and a value trap. In these conditions, the asymmetry remains indiscernible. A quantified catalyst, such as the publication of annual results or the Form 10-K, is required to establish a solid valuation.

Bull case

The group, a large-cap pharmaceutical distributor rated AAA, benefits from defensive exposure supported by the EXPANSION macroeconomic regime, with an indicator at 0,58. Technical momentum is supported: the stock trades 6,3 % above the 50-session moving average and 15,7 % above the 200-session moving average. The opioid litigation appears largely provisioned, and the risk is mostly transferred to manufacturers. Short-seller positioning is neutral, with a z-score of -0,15.

Bear case

The 15,7 % rise relative to the long-term moving average is not backed by any quantified fundamental catalyst. Residual opioid litigation risk remains, with 1,8 billion dollars over six years. Potential competition from Amazon Pharmacy, McKesson or Cencora is not confirmed by quantified elements, while accounting opacity persists in the absence of public ratios on net debt, ROIC or PER.

Scenarios

The bullish scenario (35 %) assumes that the annual results confirm the guidance and the share repurchases. The central scenario (50 %) assumes a continuation of trendless movement in the current zone, below the long-term moving average raised by 15 %. The bearish scenario (15 %) corresponds to a decline in the event of guidance disappointment or a resurgence of opioid litigation.

Risks

Risks include guidance disappointment, a resurgence of opioid litigation, and a lack of visibility on competitive pressures from Amazon Pharmacy, McKesson and Cencora. Accounting opacity constitutes an additional risk.

Market positioning (short sellers)

Short interest / shares outstanding: 2.75 %
Days to cover: 2.85
Settlement date: 2026-08-14
Source: FINRA (disseminated on 2026-08-26)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (2/3)	No new quantified fact has emerged. The case remains pending for lack of updated fundamental data.

Frequently asked questions

Why is the signal weak even though the macro context is bullish?

The signal combines favorable quantitative indicators, such as the expansionary macroeconomic regime and the technical picture, but fundamental analysis has no verified ratio (PER, debt/EBITDA, ROIC). The internal vote, at 2/3, limits confidence. The absence of a quantified catalyst leaves the asymmetry completely indeterminate.

What are the main bullish arguments for the case?

The bull case rests on the status of a pharmaceutical distributor with an AAA rating, on a defensive business favored by the expansionary macroeconomic regime, and on solid technical momentum. The opioid litigation appears largely provisioned. Short-seller positioning is neutral, which limits the risk of a violent short squeeze.

What are the arguments from the bearish camp?

The bearish arguments stem from a 15,7 % gain relative to the long-term moving average without any quantified fundamental catalyst. Residual opioid risk is not entirely eliminated, with 1,8 billion dollars over six years. The lack of visibility on competition from Amazon Pharmacy, McKesson and Cencora, as well as accounting opacity, reinforces caution.

What event could shift the thesis?

The publication of annual results (FY26) or the Form 10-K would constitute a quantified catalyst. Such data would allow net debt, EBITDA, ROIC and PER to be updated, and the asymmetry between quality value and value trap to be defined. The bullish scenario assumes confirmation of the guidance and of the share repurchases.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

August 11, 2026 — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)
August 11, 2026 — 10-K (SEC · 10-K)
August 5, 2026 — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers (SEC · 8-K)
April 30, 2026 — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 5, 2026 at 07:15 (UTC).
Interests: no position in the stock analysed (CAH) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.